Abstract
Thailand is the only country that has conducted two Phase III efficacy trials and ten other Phase I/II studies using various HIV-1 vaccine constructs. This outstanding record is the result of strong efforts and commitment among various partners, including policy makers, regulators, researchers and foreign collaborators. Recently, it has become apparent that hardly any new HIV/AIDS candidate vaccines are in the pipeline reaching the stage of clinical testing, especially a candidate vaccine that is suitable for Thailand and the surrounding region. However, many lessons learned can be utilized or modified for other vaccine trials, particularly vaccines against other infectious diseases prevalent in developing countries.
| Original language | English |
|---|---|
| Pages (from-to) | 311-317 |
| Number of pages | 7 |
| Journal | Expert Review of Vaccines |
| Volume | 7 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Apr 2008 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Clinical research
- HIV vaccine
- Lessons learned
- Thailand
Fingerprint
Dive into the research topics of 'HIV vaccine research in Thailand: Lessons learned'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver